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ABSTRACT
Periodontitis is a major cause of adult tooth loss and is characterized by bacteria-induced inflammation and 
periodontal destruction. The ultimate goal of periodontal therapy is not only to slow down the development 
of periodontal disease, but also to regenerate the architectural and functional integrity of the periodontal 
complex, which includes the formation of new cementum together with a new connective tissue attachment 
between the newly formed bone and cementum.
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INTRODUCTION
Periodontitis is a major cause of adult tooth loss 
and is characterized by bacteria-induced inflamma-
tion and periodontal destruction. The ultimate goal 
of periodontal therapy is not only to slow down the 
development of periodontal disease, but also to re-
generate the architectural and functional integrity 
of the periodontal complex, which includes the for-
mation of new cementum together with a new con-
nective tissue attachment between the newly formed 
bone and cementum (1).
Regeneration uses the principles of guided tis-
sue regeneration (GTR) (2) and guided bone regen-
eration (GBR) as modern techniques in implantolo-
gy and periodontology. Their main goal is to restore 
lost tissues, creating a perfect condition for implant 
placement or tooth preservation.
Periodontal Regeneration 
Periodontal regeneration uses bone restorative 
materials to “fill” periodontal defects. Many tech-
niques have been developed focusing on the search 
for the ideal materials for regeneration - autograft, 
allograft, xenograft and various artificial bone re-
placements (3). The autograft is considered a gold 
standard for periodontal regeneration. Other alter-
natives are used to restore the periodontium to avoid 
a second surgical site and complications such as an-
kylosis and root resorption. Various allografts, xeno-
grafts, and synthetic materials such as DFDBA, inor-
ganic bovine bone, hydroxyapatite (HA) and trical-
cium phosphate (TCP) are available and widely used 
materials. Also, biocomposite hydroxyapatite is suc-
cessfully used for periodontal regeneration (4). Some 
authors report full bone regeneration and high vol-
ume stability around implants using high porosity 
synthetic biphasic calcium phosphate, sintered de-
proteinized bovine bone mineral, and synthetic two-
phase nano-hydroxyapatite paste in combination 
with a pericardial collagen membrane (5).
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The use of biological mediators may selective-
ly increase cell repopulation in the periodontium. 
Combination of biologically active agents with scaf-
fold materials may positively influence the treatment 
of intraosseous defects (6). EMD, PRP, PRF, biomate-
rials derived from human organisms or animals have 
been extensively investigated and clinically adminis-
tered in periodontal regeneration (7-13).
EMD in Periodontal Regeneration
In recent decades EMD has been available as a 
biological regenerative material. It is derived from the 
developing porcine teeth and contains a mixture of 
low-molecular weight proteins that can be absorbed 
on the hydroxyapatite and collagen fibers at the root 
surface and cause cementum formation (7-9). EMD 
induces angiogenesis of human microvascular cells 
(14). EMD acts as a cytostatic agent on cultured ep-
ithelial cells and can thus favor regeneration of the 
periodontium by inhibiting or delaying epithelial re-
generation (10).
Its effects are compared with those with open 
flap debridement (OFD) and other surgical proce-
dures such as GTR or combined approaches in the 
treatment of periodontal intraosseous defects (8,15-
17). OFD followed by further administration of EMD 
may lead to significantly greater clinical attachment 
gain compared to OFD used alone (17,18). Most stud-
ies show that there is almost no advantage of EMD 
when used with bone graft materials (bovine bone 
mineral, nanocrystalline hydroxyapatite and bipha-
sic calcium phosphate) (13,19-22).
Several studies show histological evidence of 
periodontal regeneration using EMD (9,23-26). EMD 
was observed on the root surface for 4 weeks post-
application, and early signs of regeneration were ob-
served after 2 to 6 weeks (27,28).
EMD has been shown to achieve an average re-
duction in probing depth (PD) of 3.8 to 4.9 mm and 
an average clinical attachment level (CAL) of 2.2 to 
3.4 mm, (8,17,29-31) as well as 74% bone fill of  the 
defect (17).
Because of its semi-liquid consistency, EMD has 
a limited space-building potential, which in turn can 
lead to collapse of the flap (23). The bone restorative 
material helps to overcome the risk of collapse of the 
flap after application of EMD, especially in deep in-
traosseus defects and provide space for the regener-
ation process and at the same time allows the EMD 
to support periodontal regeneration (32). Boyan et al. 
(33) have found that the addition of 4 mg of EMD 
to DFDBA increases the amount of bone induction 
and new bone formation compared to DFDBA alone. 
Rosen (34) demonstrates the clinical benefits of us-
ing a combined therapeutic approach where EMD is 
combined with DFDBA or FDBA. Harrelet al. suc-
cessfully used DFDBA mixed with EMD with min-
imally invasive surgery to treat 130 periodontal de-
fects (35). Hoidal et al. (19) found that the addition 
of EMD to DFDBA did not provide a statistically sig-
nificant improvement in measured soft and hard tis-
sue parameters compared to DFDBA alone 6 months 
after surgery.
In 2002, Velasquez-Plata et al. (36) examined 
the use of EMD alone or in combination with xeno-
graft and did not detect a significant difference be-
tween the groups with respect to PD reduction or 
CAL gain. Lekovic et al. (37) show a greater reduc-
tion in probing depth, clinical attachment gain, and 
bone fill with a combination of xenograft and EMD 
compared to EMD alone.
In an attempt to determine whether bone fill 
material plays a role in the potential beneficial effects 
of EMD addition, Gurinsky et al. (38) examined the 
combination of DFDBA and EMD and EMD alone, 
demonstrating significantly more bone filling in the 
combined group but no difference in probing depth 
reduction and clinical attachment gain.
In summary, EMD is a protein preparation of 
developing porcine teeth that contains a mixture of 
low-molecular weight proteins. When applied to the 
root surface, the proteins are absorbed into the hy-
droxyapatite and collagen fibers, causing cement for-
mation, followed by periodontal regeneration. Clini-
cal use of EMD may be characterized as safe with ex-
cellent clinical outcomes and limited complications. 
EMD alone or in combination with bone graft ma-
terials provides excellent clinical outcome and long-
term stability (8,29).
PRP in Periodontal Regeneration
PRP and PRF are the two generations of plate-
let concentrates obtained by treating autogenous 
blood samples by centrifugation. PRP is an autolo-
gous highly concentrated platelet product (39) and 
its preparation requires anticoagulants at the time of 
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taking blood-thymidine and calcium chloride. This 
product is derived from a centrifuged blood sample 
that contains high concentration of platelet growth 
factors, insulin-like growth factor, and fibroblast 
growth factor (40). In addition, the lower pH of PRP 
(6.5-6.7) compared to normal blood (7-7.2) can in-
crease bacteriostatic and bactericidal properties (41). 
Unlike PRP, PRF is centrifuged blood without any 
additives (10).
Both PRP and PRF contain highly concentrated 
growth factors such as transforming growth factor-
b (TGF-b), platelet derived growth factor (PDGF), 
vascular growth factor (VEGF), insulin-like growth 
factor (IGF), epithelial growth factor, and fibroblast 
growth factor-b (FGF-b)(42).
Wiltfanget al. (43) evaluated immunohistologi-
cally the use of PRP in the regeneration of bone de-
fects of the skull of minipigs by treating them with b-
TCP with or without PRP and found that the addi-
tion of PRP did not affect bone regeneration and did 
not add any additional benefit. The same team (44) 
compared b-TCP and PRP / b-TCP sinus floor eleva-
tions at the 6th month and reported 8 to 10% more 
bone formation with PRP / b-TCP, but the difference 
was statistically insignificant.
Velichet et al. (45) evaluated the efficacy of b-
TCP and hydroxyapatite bone graft materials and 
the PRP / b-TCP combination in the treatment of 
mandibular defects  reporting that all treatment ap-
proaches were successful and the PRP / b-TCP group 
showed a faster formation of new bone and bone re-
modeling at the end of the first year.
Dori et al. (46) treated periodontal intraosseus 
defects with a combination of b-TCP / GTR with or 
without PRP and at the end of the first year no statis-
tically significant differences were observed in any of 
the clinical parameters in either group and no addi-
tional clinical benefits for PRP.
In an experimental study, Kovacs et al. (47) 
compared b-TCP and PRP / b-TCP combinations 
and assessed histologically the bone formation in 
bone defects after premolar extraction in dog lower 
jaw. They found significantly greater bone formation 
in the PRP / b-TCP group at week 12. In another ex-
perimental study of similar design, Kovacs et al. (48) 
reported a significant difference in favor of the PRP 
/ b-TCP group at week 12 and concluded that the use 
of PRP accelerated remodeling of b-TCP and result-
ed in the formation of bone with a quality similar to 
autogenous bone.
Yassibag-Berkman et al. (49) evaluated the effi-
cacy of b-TCP, PRP / b-TCP, and PRP / b-TCP / GTR 
in the treatment of two- and three-wall intraosse-
ous defects, and reported an improvement in all pa-
rameters tested compared to the baseline.Howev-
er, PRP did not add significant clinical benefit after 
6 months. These results are confirmed by other au-
thors (50).
Some studies (51-53) have shownthat optimal 
clinical results with GTR in combination with bone 
graft materials with or without PRP have been ob-
tained in the first year following regenerative thera-
py of intraosseous defects.
S. Peev and D. Atanasov (54) have shown in 
theirown research on 86 implants that the use of 
PRP withimmediate loaded implants improves the 
stability.
CONCLUSION
The data on the different approaches are con-
tradictory and therefore more research is need-
ed. The combination of EMD and bone grafts may 
result in additional clinical improvements in terms 
of CAL gain and PD reduction compared with those 
obtained with EMD alone. Platelet-derived concen-
trates have been shown to enhance soft tissue heal-
ing which indirectly can create a better environment 
for bone growth.Futurestudiestestingthe efficacy of 
this materials promoting GBR, GTR and treatment 
of peri-implant defects are needed.
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